Metreleptin
Orphan Drug Cold Chain RequiredFDA Approved
Description
Metreleptin is a recombinant analog of human leptin used as replacement therapy for complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. It helps regulate metabolic abnormalities including severe hypertriglyceridemia and diabetes mellitus. The drug is indicated for drug-induced lipodystrophy when associated with metabolic complications.
Indications & Therapeutic Use
Generalized lipodystrophy, drug-induced lipodystrophy with metabolic complications
Linked Diseases:
Global Availability (6 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Metreleptin
| Generic Name | Metreleptin |
| Brands | 1 brand available |
| Active Ingredient | Metreleptin |
| Drug Class | Generalized lipodystrophy |
| Manufacturer | Amryt Pharma |
| Dosage Forms | Subcutaneous injection, 11.3mg powder for reconstitution |
| Medical Code | A16AX08 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 21 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00677313 |
| Countries | 6 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations7 Validated Nodes